Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005793 · ClinicalTrials.gov registry record · Phase 4
Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients
A Phase 4 study of Vascular Diseases and Kidney Transplant; Complications, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05005793 is a Phase 4 study of Vascular Diseases and Kidney Transplant; Complications that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 120 participants, below the 558-participant average among 40 other Vascular Diseases trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05005793, a Phase 4 study of Vascular Diseases and Kidney Transplant; Complications, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Lower serum bicarbonate levels, even within the normal laboratory range, in kidney transplant recipients (KTRs) are associated with an increased risk of graft loss, cardiovascular events and mortality. Because acid retention is common in KTRs, it is plausible that alkali therapy in KTRs may also result in improved vascular and graft function. The investigators will perform a randomized, double-blinded, placebo-controlled, 12 month study in 120 KTRs to examine the effect of sodium bicarbonate therapy on surrogate markers of CVD and graft function. The overall hypothesis is that treatment with bicarbonate will improve indicators of vascular and graft function in KTRs by decreasing complement activation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sodium bicarbonate
Study Locations (1)
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2026-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005793
The ClinicalTrials.gov registry entry for NCT05005793 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 558-participant average among 40 other Vascular Diseases trials with a reported enrollment target (78% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Vascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05005793 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05005793 about?
NCT05005793 is a clinical study titled "Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients". Lower serum bicarbonate levels, even within the normal laboratory range, in kidney transplant recipients (KTRs) are associated with an increased risk of graft loss, cardiovascular events and mortality. Because acid retention is common in KTRs, it is plausible that alkali therapy in KTRs may also res...
What is the current status of trial NCT05005793?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2021-12-01. Estimated completion is 2026-08-31.
What conditions does trial NCT05005793 study?
This clinical trial studies the following conditions: Vascular Diseases, Kidney Transplant; Complications, Metabolic Acidosis.
What interventions are being tested in trial NCT05005793?
The interventions under investigation include: Placebo (DRUG), Sodium bicarbonate (DRUG).
Who is sponsoring clinical trial NCT05005793?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05005793 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
RECRUITING · Phase 4
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
COMPLETED · Phase 4
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.